MT-1303-Middle

DRUG3 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Plaque PsoriasisRelapsing-remitting Multiple Sclerosis

Phase 2

Dose-finding Study of MT-1303

CompletedNCT01742052

Tanabe Pharma CorporationRelapsing-remitting Multiple Sclerosis

Start: 2013-01-31End: 2014-10-31Updated: 2016-09-14

Extension Study of MT-1303

CompletedNCT01890655

Tanabe Pharma CorporationRelapsing-remitting Multiple Sclerosis

Start: 2013-08-31End: 2016-03-31Updated: 2016-04-11

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT01987843

Tanabe Pharma CorporationPlaque Psoriasis

Start: 2013-09-30End: 2014-11-30Updated: 2014-12-18

Related Papers

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

2016-08-1644 citations